KMTS Stock Forecast & Price Target

Kestra Medical Techs is attractive fundamentally because it is posting rapid commercial traction, with F1Q27 sales of $31.0M, up 60% y/y, and FY27 revenue guidance raised to $141M, signaling a durable beat-and-raise cadence. Its profitability profile is improving as gross margin expanded to 56.5% from 45.7% a year earlier, marking the 11th consecutive quarter of sequential expansion, while in-network mix, stronger reimbursement execution, and market share gains continue to lift revenue quality. The company also has a strong balance sheet with about $320M of liquidity, giving it ample runway to fund commercialization and R&D, and its ASSURE platform sits in a large U.S. WCD market where penetration remains only 30% to 50%.

Kestra Medical Techs is viewed negatively because its 7.4x forward PS valuation already implies a rich premium to the 3.1x Small-Cap MedTech universe, leaving limited room for error despite an early commercial ramp. Although ASSURE has roughly 15% unit share and quarterly revenue has nearly doubled to $28.6M since the March 2025 IPO, the business still faces commercialization, reimbursement, and balance sheet risks, plus lower revenue per fitting of about $5,400 by FY26. Its WCD market remains controversial and heterogeneous, with uncertain mortality benefit, dependence on compliance above 22 hours per day, and ongoing concerns about false alarms and competition.